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ABSTRACT 
 
Introduction: Tuberculosis is a major health problem in India. India accounts for 26% of global TB burden. HIV-
TB coinfection is commonly seen. WHO and RNTCP India recommends screening of all newly diagnosed HIV 
patients with a cartridge based nucleic acid amplification test called Gene Xpert. Aim: To study the incidence of 
Pulmonary Tuberculosis in newly diagnosed HIV patients. Methods: All newly diagnosed HIV positive patients 
were referred from HIV Centre to Pulmonary Medicine OPD for screening of tuberculosis before starting anti-
retroviral drugs. Patients underwent sputum Gene Xpert apart from other investigations required as per clinical 
examination. 210 such patients were screened for pulmonary tuberculosis from March 2016 to December 2016 and 
were included in the study. Results: A total of 210 patients were included in the study undergoing Gene Xpert. In 24 
(11.42%) HIV positive patients, MTB was detected. 2(0.95%) patients were rifampicin resistant. Conclusion: 
Screening with Gene Xpert in all HIV positive patients helps in early diagnosis and treatment of TB and active case 
finding of patients with drug resistant tuberculosis. The results are available in less than 2 hours. Use of Gene Xpert 
will thus help in reducing morbidity, mortality and transmission of tuberculosis. 
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Introduction 
 
 
 
Tuberculosis is a major public health problem in India 
and worldwide. According to the World Health 
Organization (WHO) global TB report of 2015[1], 
India accounts for 26% of the total global TB burden. 
2.0-2.5million new cases are added annually. Out of all 
TB notified cases in India, 53% are smear positive 
cases, 28% are smear negative cases and 19% are extra 
pulmonary cases. It is estimated that 2.2% cases of TB 
in India are of MDR TB. 4% of patients of TB in India 
are HIV positive.[2]. In 2015, HIV prevalence in India 
was an estimated 0.26%.[3]This figure is small 
compared to most other middle-income countries but 
because of India's huge population (1.2 billion) this  
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equates to 2.1 million people living with HIV.[4] TB 
cases are increasing worldwide after HIV epidemic and 
development of multidrug resistance tuberculosis. 
Gene Xpert MTB/RIF, a new nucleic acid 
amplification technology, offers rapid and accurate 
diagnostic results from biological specimens with 
minimal staff training requirements [5,6,7]. It has 
showed high sensitivity and specificity for the 
diagnosis of active TB (97% and 99.2%, respectively) 
and the detection of rifampicin (RIF) resistance (97.6% 
and 98.1%, respectively), the cornerstone of TB 
treatment regimens . A recent review of published 
evaluation reports confirmed that the use of Xpert as an 
initial test replacing smear microscopy was highly 
accurate [6]. In 2010 and with the encouraging initial 
evaluation reports, the WHO endorsed Xpert to be used 
as the initial TB diagnostic test for individuals with 
HIV-infection or those suspected of having MDR-TB 
[8].The most common method to diagnose pulmonary 
TB is sputum AFB smear. Sputum AFB smear by 
fluorescent technique can detect TB in 20-80% cases 
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[10]. Sufficient bacillary load is a must for Sputum 
AFB smear. It cannot detect drug resistance. As the 
numbers of bacilli in sputum of severely 
immunosuppressed HIV patients is low, TB often goes 
undetected with sputum AFB smear [9]. 
 
Methods 
 
The study was carried in department of pulmonary 
medicine of H.B.T. Medical college and R.N. Cooper 
hospital, Mumbai. All newly diagnosed HIV patients 
were referred from HIV OPD to Pulmonary Medicine 
OPD for ruling out tuberculosis infection. Patients 
underwent Chest X-ray, Sputum ZN staining and USG 
abdomen routinely. Additional investigations were 
done as per clinical findings. All these patients were 
given falcon tubes to collect 2 morning sputum 
samples for cartridge based nucleic amplification 
testing i.e. Gene Xpert. Gene Xpert gave result of MTB 
detection and its resistance to rifampicin in 2 hours. 
210 such patients from March 2016 to December 2016 
were included in the study.  
  
Results 
 
A total of 210 patients were included in the study 
undergoing. In 24 (11.42%) HIV positive patients, 
MTB  was detected. 2(0.95%) patients were rifampicin 
resistant. The incidence of both HIV and HIV TB 
coinfection were higher in 3
rd
, 4
th
 and 5
th
 decade of life.  
 
 
Table 1: MTB detected on gene xpert vs number of patients and their respective age 
 
Age No of HIV patients MTB detected on Gene Xpert 
< 20 8 0 
21-30 31 4 
31-40 70 8 
41-50 63 9 
51-60 32 3 
>60 6 0 
Total 210 24 
 
Out of 210 patients 76 were females and 134 were males. MTB was detected in 8 out of 76 female patients 
and 16 out of 134 male patients. The incidence of HIV TB coinfection was almost equal in both males and females. 
 
Table 2: MTB detected on gene xpert vs number of patients and their sex 
 
Sex  No of HIV patients MTB detected on Gene Xpert 
Male  76 8 
Female 134 16 
 
Discussion 
 
Our study aimed for screening pulmonary tuberculosis 
in newly diagnosed HIV patients. In the past sputum 
ZN staining was routinely used for screening HIV 
patients. There needs to be 10000 bacilli/ml of sputum 
to be graded as sputum positive.[11]  In our study, 
Gene Xpert helped in over diagnosis of pulmonary TB 
in sputum smear negative HIV patients. The sensitivity 
of Gene Xpert in detecting tuberculosis in HIV positive 
patients was 93.9%.[12]Gene Xpert gives the results in 
2 hours only and also resistance to rifampicin. 
Resistance to Rifampicin is a surrogate marker of 
MDR Tuberculosis.[13]Our study showed 11.42% 
newly diagnosed HIV patients to have Pulmonary 
tuberculosis. A similar study was carried out in newly 
detected HIV positive prisoners in Malaysia. Gene 
Xpert detected MTB in 12% patients.[14]. In 2014, 
Nguyen T et al found Rifampicin resistance in 3.7% of 
HIV positive patients with Tuberculosis[15]. In 2009, 
Rajsekaran S et al found that HIV was found to coexist 
with 14.2 % of Multi drug resistant TB 
patients[16].Our study showed Rifampicin resistance in 
0.95% patients. Bansal D el al carried a similar study in 
which the incidence of rifampicin resistance was 
0.99% in newly diagnosed HIV patients.[17]Early 
diagnosis of pulmonary tuberculosis in HIV patients 
helps in decreasing morbidity and mortality in TB-HIV 
patients and decreasing transmission and emergence of 
drug resistance. WHO and RNTCP India has 
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recommended Gene Xpert as the primary test for 
screening tuberculosis in newly diagnosed HIV 
patients.[18] 
 
Conclusion 
 
Gene Xpert detects MTB in HIV with greater efficacy 
than sputum microscopy, also helps in diagnosis in less 
than 2 hours. It detects rifampicin resistance with high 
sensitivity and specificity and can be used for 
screening for MDR-TB so that early therapy can be 
started, thus decreasing the incidence of MDR-TB. 
WHO recommends Gene Xpert for diagnosis of 
pulmonary tuberculosis and rifampicin resistance, 
especially in PLHIV and re-treatment cases who are at 
risk of MDR-TB11 
 
 
References 
 
1. "Global TB Report". www.who.int 
/tb/publications/global_report,2015. 
2. "RNTCP India Training Module 1-4". 
www.tbcindia.nic.in, 2010 
3. NACO (2015) „Annual report 2015 -16‟ 
4. UNAIDS (2016) 'Prevention Gap Report' 
5. Boehme CC, Nabeta P, Hillemann D, Nicol MP, 
Shenai S et al. Rapid Molecular Detection of 
Tuberculosis and Rifampin Resistance. N Engl J 
Med .2010;363: 1005–1015 
6. Steingart K, Sohn H, Schiller I, Kloda L, Boehme 
C et al. (2013) Xpert® MTB / RIF assay for 
pulmonary tuberculosis and rifampicin resistance 
in adults (Review ). Cochrane Database of 
Systematic Reviews: Art. No: CD009593 
7. Chang K, Lu W, Wang J, Zhang K, Jia S et al. 
Rapid and effective diagnosis of tuberculosis and 
rifampicin resistance with Xpert MTB/RIF assay: 
a meta-analysis. J Infect.2012; 64: 580–588.  
8. World Health Organization (WHO) (2011) Rapid 
Implementation of the Xpert MTB / RIF 
diagnostic test: technical and operational “How-
to”; practical considerations. Geneva 
9. Barnes PF, Bloch AB, Davidson PT, et al. 
Current concepts: Tuberculosis in patients with 
human immunodeficiency virus infection. N Engl 
J Med. 1991;324(23):1644–1650 
10. A, Pai M. Optimizing sputum smear microscopy 
for the diagnosis of pulmonary tuberculosis. 
Expert Rev Anti Infect Ther. 2007;5(3):327–331. 
11. Allen BW, Mitchison DA. Counts of viable 
tubercle bacilli in sputum related to smear and 
culture grading. Med Lab Sci 1992; 49: 94 
12. “Policy statement: Automated real-time nucleic 
acid amplification technology for rapid and 
simultaneous detection of tuberculosis and 
rifampicin resistance: Xpert MTB/RIF system”, 
WHO, Geneva, 2011www.who.int/tb/ 
features_archive/xpert_rapid_tb_test/ - See more 
at:http://www.tbfacts.org/xpert-tbtest/#sthash 
.amc3vei9.dpuf 
13. “Two hour detection of MTB and resistance to 
rifampicin”, Cepheid International, 2011 
www.cepheidinternational.com 
14. The Diagnostic Performance of a Single 
GeneXpert MTB/RIF Assay in an Intensified 
Tuberculosis Case Finding Survey among HIV-
Infected Prisoners in Malaysia. Haider AD, 
Humaira AR, Kee PN, Frederick 
LA,Kamarulzaman A. Plos one. 2013;8(9):e7371 
15. Ngyuyen T, et al. Evaluation of Gene Xpert 
MTB/RIF for Diagnosis of Tuberculous 
Meningitis. J Clin Microbiol. 2014;52(1):226-233 
16. Rajasekaran S, Chandrasekar C. HIV coinfection 
among multidrug resistant and extensively drug 
resistant tuberculosis patients – a trend. J Indian 
Med Assoc. 2009;107(5):281-6. 
17. Bansal D, Avashia S, Karothiya M. A. Study of 
Gene Xpert in Screening of Sputum in HIV 
Positive Patients Presenting to Tertiary Care 
Centre. Ntl J Community Med 2016; 7(8):657-
660. 
18. WHO Policy statement: automated real-time 
nucleic acid amplification technology for rapid 
and simultaneous detection of tuberculosis and 
rifampicin resistance: Xpert MTB/RIF system 
2011. Available at: http://www.who.int/tb/ 
laboratory/en/ 
 
 
Source of Support: Nil                                     
Conflict of Interest: None  
 
 
